{"filing":{"accession_number":"0001628280-26-051041","cik":"0001830214","ticker":"DNABW","company_name":"Ginkgo Bioworks Holdings, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"dna-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828026051041/dna-20260730.htm"},"events":[{"id":22680,"run_id":20517,"accession_number":"0001628280-26-051041","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The filing announces a presentation and Q\u0026A session to review \"business performance for the second quarter ended June 30, 2026\" scheduled for August 5, 2026. This is a notice of an upcoming earnings presentation disclosing Q2 2026 results. Although the actual financial results are not yet disclosed in this 8-K, the announcement of the earnings presentation date and the commitment to review quarterly business performance constitutes an earnings-related disclosure material to investors.","company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNABW","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22693,"accession_number":"0001628280-26-051041","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing announces a presentation and Q\u0026A session to review \"business performance for the second quarter ended June 30, 2026\" scheduled for August 5, 2026. This is a notice of an upcoming earnings presentation disclosing Q2 2026 results. Although the actual financial results are not yet disclosed in this 8-K, the announcement of the earnings presentation date and the commitment to review quarterly business performance constitutes an earnings-related disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:11.351621+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22693,"accession_number":"0001628280-26-051041","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing announces a presentation and Q\u0026A session to review \"business performance for the second quarter ended June 30, 2026\" scheduled for August 5, 2026. This is a notice of an upcoming earnings presentation disclosing Q2 2026 results. Although the actual financial results are not yet disclosed in this 8-K, the announcement of the earnings presentation date and the commitment to review quarterly business performance constitutes an earnings-related disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:17:11.351621+00:00","company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNABW","filing_date":"2026-07-30"}]}